Matrix metalloproteinases and proangiogenic factors in testicular germ cell tumors

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 116-121

  Diamantopoulos, Nikolaos ^a   Boutis, A L ^b   Koratzis, I ^a   Andreadis, C ^a   Galaktidou, G ^a   Mouratidou, D ^a   Kortsaris, A ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b 2nd IKA General Hospital   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Angiopoietin; Germ cell rumors; Matrix metalloproteinases; Proangiogenic factors; Testicular cancer

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR BB; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; GERM CELL TUMOR; HUMAN; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; PATHOGENESIS;

ADULT; ANGIOGENIC PROTEINS; ANGIOPOIETIN-2; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PLATELET-DERIVED GROWTH FACTOR; TESTICULAR NEOPLASMS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950987850     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bosl GJ, Sheinfeld J, Bajorin DF et al. Cancer of the testis. In: De Vita VT, Hellman S, Rosenberg SA (Eds): Cancer: Principles and Practice of Oncology (7th Edn). Philadelphia: Lippincott Williams and Wilkins, pp 1269-1293.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007; 13: 535-541. (Pubitemid 350123764)
4. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
5. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68. (Pubitemid 10098769)
6. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166. (Pubitemid 34309470)
7. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630. (Pubitemid 30616366)
8. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297. (Pubitemid 40387607)
9. Giannelli G, Antonaci S. Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. Histol Histopathol 2002; 17: 339-345. (Pubitemid 34116435)
10. Baker AH, Ahonen M, Kähäri VM. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol 2000; 465: 469-483. (Pubitemid 32193357)
11. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 444-447.
12. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225. (Pubitemid 32176299)
13. Rauvala M, Aglund K, Puistola U et al. Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 2006; 16: 1297-1302.
14. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest 2001; 48: 31-43.
15. Davies B, Miles DW, Happerfield LC et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-1131. (Pubitemid 23147516)
16. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001; 31: 213-219. (Pubitemid 32107018)
17. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969. (Pubitemid 27098025)
18. Basciani S, Mariani S, Arizzi M et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. J Clin Endocrinol Metab 2002; 87: 2310-2319. (Pubitemid 34521525)
19. Fukuda S, Shirahama T, Imazono Y et al. Expression of VEGF in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999; 85: 1323-1330.
20. Jones A, Fujiyama C, Turner K et al. Angiogenesis and lymph-angiogenesis in stage 1 germ cell tumours of the testis. BJU Int 2000; 86: 80-86. (Pubitemid 30420769)
21. Maher TM, Lee AH. Vascular density does not predict future metastatic disease in clinical stage 1 non-seminomatous germ cell tumours of the testis. Histopathology 1998; 32: 217-224.
22. Olivarez D, Ulbright T, DeRiese W et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994; 54: 2800-2802. (Pubitemid 24173777)
23. Viglietto G, Romano A, Maglione D et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996; 13: 577-587. (Pubitemid 26283854)
24. Bentas W, Beecken WD, Glienke et al. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors Urol Res 2003; 30: 390-393.
25. Boutis AL, Diamantopoulos N, Mouratidou D et al. Serum proangiogenic factors in patients with testicular germ cell tumors. Proc Amer Soc Clin Oncol 2008; 26(15S-I): 675s(abstr).
26. Greene FL, Paige DL, Fleming ID et al (Eds). AJCC Cancer Staging Manual (6th Edn). New York: Springer-Verlag, 2002, pp 347-354.
27. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
28. Nelson AR, Fingleton B, Rothenberg ML et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149. (Pubitemid 30123793)
29. Woessner JF. 1998. The matrix metalloproteinase family. In: Parks WC, Mecham RP (Eds): Matrix Metalloproteinases. San Diego: Academic Press, 1998, pp 1-14.
30. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-970. (Pubitemid 32706688)
31. Kanda K, Takahashi M, Murakami Y et al. The role of the activated form of matrix metalloproteinase-2 in urothelial cancer. BJU Int 2000; 86: 553-557.
32. Gohji K, Fujimoto N, Hara I et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101. (Pubitemid 28157734)
33. Klahr S, Talvensaari-Mattila A, Paakko P et al. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 1270-1275. (Pubitemid 37363416)
34. Gomez DE, Alonso DF, Yosiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
35. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest 2001; 48: 31-43.
36. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999; 878: 271-289.
37. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
38. Robey R. Angiogenesis. Hidden signatures written in blood. Nat Rev Cancer 2007; 7: 571.
39. Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83: 535-555. (Pubitemid 29150246)
40. Leitzel K, Bryce W, Tomita J et al. Elevated plasma platelet-derived growth factor B-chain levels in cancer patients. Cancer Res 1991; 51: 4149-4154.
41. Szarvas T, Jäger T, Droste F et al. 2008; Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer. Pathol Oncol Res 2008 Sep 20 [Epub]. Available http://www.ncbi.nlm.nih.gov/sites/entrez via the INTERNET. Accessed 2008 Dec 28.
42. Halvorsen OJ. Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS 2008; (Suppl) 123: 5-62.
43. Tuo QH, Zeng H, Stinnett A. et al. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol 2008; 294: 2547-2557.
44. Lai DM, Li H, Lee CC et al. Angiopoietin-like protein 1 decreases blood brain barrier damage and edema following focal cerebral ischemia in mice. Neurochem Int 2008; 52: 470-477.
45. Haugnes HS, Aass N, Fossa SD et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2008; 2: 128-137.